International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 4 , Pages 997-1002 , 15 March 2009

ACR Appropriateness Criteria® on Postmastectomy Radiotherapy: Expert Panel on Radiation Oncology—Breast

  • Marie E. Taylor, M.D.

      Affiliations

    • Washington University, Saint Louis, Missouri
    • Corresponding Author InformationReprint requests to: Marie E. Taylor, M.D., Department of Radiation Oncology Washington University, 4921 Parkview Place, Box 8224 St. Louis, MO 63110-1032. Tel: (314) 362-8567
    • ,
  • Bruce G. Haffty, M.D.

      Affiliations

    • University of Medicine and Dentistry, New Jersey—Robert Wood Johnson Medical School, New Brunswick, New Jersey
    • ,
  • Rachel Rabinovitch, M.D.

      Affiliations

    • University of Colorado Cancer Center, Denver, Colorado
    • ,
  • Douglas W. Arthur, M.D.

      Affiliations

    • Medical College of Virginia, Richmond, Virginia
    • ,
  • Francine E. Halberg, M.D.

      Affiliations

    • Marin Cancer Institute, Greenbrae, California
    • ,
  • Eric A. Strom, M.D.

      Affiliations

    • University of Texas, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Julia R. White, M.D.

      Affiliations

    • Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Melody A. Cobleigh, M.D.

      Affiliations

    • Rush University Medical Center, Chicago, Illinois, American Society of Clinical Oncology
    • ,
  • Stephen B. Edge, M.D.

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York, and American College of Surgeons

Received 24 October 2008 ,Accepted 29 October 2008.

References 

  1. Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol. 1995;13:2869–2878
  2. Axelsson CK, Blichert-Toft M. Low-risk breast cancer patients treated by mastectomy and lower axillary dissection. The present status of the Danish Breast Cancer Cooperative Group Trial 77-A. Acta Oncol. 1988;27:605–609
  3. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996;14:1982–1992
  4. Morrison JM, Kelly KA, Howell A, et al. West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer. J Natl Cancer Inst Monogr. 1992;(11):85–88
  5. Senn HJ, Barett-Mahler AR, Jungi WF, et al. Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients: 10 year results. Eur J Cancer Clin Oncol. 1989;25:513–525
  6. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol. 1994;5:717–724
  7. Fisher B, Fisher ER, Redmond C. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 1986;4:929–941
  8. Morrison JM, Howell A, Kelly KA, et al. West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. I. Patients with involved axillary lymph nodes. Br J Cancer. 1989;60:911–918
  9. Richards MA, O'Reilly SM, Howell A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial. J Clin Oncol. 1990;8:2032–2039
  10. Rubens RD, Hayward JL, Knight RK, et al. Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet. 1983;1:839–843
  11. Fowble B, Gray R, Gilchrist K, et al. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol. 1988;6:1107–1117
  12. Jagsi R, Raad RA, Goldberg S, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: Implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005;62:1035–1039
  13. Lee JC, Truong PT, Kader HA, et al. Postmastectomy radiotherapy reduces locoregional recurrence in elderly women with high-risk breast cancer. Clin Oncol (R Coll Radiol). 2005;17:623–629
  14. Pisansky TM, Ingle JN, Schaid DJ, et al. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer. 1993;72:1247–1260
  15. Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17:1689–1700
  16. Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22:4247–4254
  17. Truong PT, Lee J, Kader HA, et al. Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy. Eur J Cancer. 2005;41:1267–1277
  18. Ahlborn TN, Gump FE, Bodian C, et al. Tumor to fascia margin as a factor in local recurrence after modified radical mastectomy. Surg Gynecol Obstet. 1988;166:523–526
  19. Huang EH, Tucker SL, Strom EA, et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:351–357
  20. Haagensen CD. Diseases of the breast. 3rd ed. Philadelphia: W.B. Saunders; 1986;
  21. Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol. 2006;24:2268–2275
  22. Recht A, Hayes DF, Eberlein TJ, et al. Local-regional recurrence after mastectomy or breast- conserving therapy. In:  Harris JR,  Lippman ME,  Morrow M, et al. editor. Diseases of the breast. Philadelphia: J.B. Lippincott; 1996;p. 649–667
  23. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: A review. Cancer. 1995;76:1491–1512
  24. Recht A, Pierce SM, Abner A, et al. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1991;9:988–996
  25. Buchholz TA, Katz A, Strom EA, et al. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002;53:880–888
  26. Donegan WL, Stine SB, Samter TG. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer. 1993;72:778–782
  27. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–1648
  28. Pierce LJ, Oberman HA, Strawderman MH, et al. Microscopic extracapsular extension in the axilla: Is this an indication for axillary radiotherapy?. Int J Radiat Oncol Biol Phys. 1995;33:253–259
  29. Hetelekidis S, Schnitt SJ, Silver B, et al. The significance of extracapsular extension of axillary lymph node metastases in early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2000;46:31–34
  30. Garg AK, Strom EA, McNeese MD, et al. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in Stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:138–145
  31. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med. 1995;332:901–906
  32. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–955
  33. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956–962
  34. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247–253
  35. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;366:2087–2106
  36. Smith BD, Smith GL, Haffty BG. Postmastectomy radiation and mortality in women with T1-2 node-positive breast cancer. J Clin Oncol. 2005;23:1409–1419
  37. Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6:557–565
  38. Gebski V, Lagleva M, Keech A, et al. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: A clinical perspective. J Natl Cancer Inst. 2006;98:26–38
  39. Thoms WW, McNeese MD, Fletcher GH, et al. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989;17:739–745
  40. Richter C, Kuhn T, Becker A, et al. Acute normal tissue reaction and local control in breast cancer patients with postmastectomy radiotherapy. [abstract] Int J Radiat Oncol Biol Phys. 1996;36:285
  41. Fletcher GH, McNeese MD, Oswald MJ. Long-range results for breast cancer patients treated by radical mastectomy and postoperative radiation without adjuvant chemotherapy: An update. Int J Radiat Oncol Biol Phys. 1989;17:11–14
  42. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: Long-term results of a randomised trial. Lancet Oncol. 2006;7:467–471
  43. Shelley W, Brundage M, Hayter C, et al. A shorter fractionation schedule for postlumpectomy breast cancer patients. Int J Radiat Oncol Biol Phys. 2000;47:1219–1228
  44. Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–1150
  45. Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: Long-term results of a randomised trial. Radiother Oncol. 2005;75:9–17
  46. Marhin W, Wai E, Tyldesley S. Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer. Int J Radiat Oncol Biol Phys. 2007;69:483–489
  47. Sheldon T, Hayes DF, Cady B, et al. Primary radiation therapy for locally advanced breast cancer. Cancer. 1987;60:1219–1225
  48. Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys. 1992;23:915–923
  49. Griem KL, Henderson IC, Gelman R, et al. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol. 1987;5:1546–1555
  50. Harris JR, Morrow M. Local management of invasive breast cancer. In:  Harris JR,  Lippman ME,  Morrow M, et al. editor. Diseases of the breast. 3rd ed. Philadelphia: J.B. Lippincott; 2004;p. 719–799

 This article summarizes the American College of Radiology Appropriateness Criteria on Postmastectomy Radiotherapy, excerpts of which are reprinted here with permission. Practitioners are encouraged to refer to the complete version at www.acr.org/ac.

 Conflict of interest: none.

PII: S0360-3016(08)03875-3

doi: 10.1016/j.ijrobp.2008.10.080

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 4 , Pages 997-1002 , 15 March 2009

Article Tools